Drug Trial Radar · NCT00685360
A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)
Last checked: Nov 19, 2026Latest source record: Dec 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
481
Actual
Start
May 8, 2008
Primary completion
Jun 11, 2010
Study completion Jun 11, 2010
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
- Sponsor type
- Industry
- First posted
- May 28, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a clinical trial to evaluate the safety and efficacy of OPC-67683 in the treatment of multidrug resistant tuberculosis (MDR TB) for 56 days. In addition to an optimized background regimen (OBR), participants will be randomized to receive: * 100 mg OPC-67683 twice daily (BID) * 200 mg OPC-67683 BID * Placebo BID After 56 days participants will complete their optimized background regimen (OBR).
Conditions
- Tuberculosis, Pulmonary
- Tuberculosis, Multidrug Resistant
- Extensively Drug-Resistant Tuberculosis
Interventions
DelamanidDrug
Delamanid was administered orally twice daily as 50-mg tablets under fed conditions in the morning and evening.
Optimized Background Regimen (OBR)Drug
Selection and administration of the treatment medications (i.e., OBRs) was based on World Health Organization (WHO's) Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country. Study Investigator could change OBR for a participant based on participant's tolerability and drug susceptibility testing (DST) results.
PlaceboDrug
Placebo tablets matching 50-mg tablets of delamanid
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Achieved Sputum Culture Conversion (SCC) Using the Mycobacteria Growth Indicator Tube (MGIT) SystemTime frame: From the first dose of study drug up to the end of the Post-treatment Follow-up Period (Up to Day 84)
- Tmax 1 and 2: Time to Maximal Peak Concentration (Tmax) for Delamanid Following First and Second Daily DoseTime frame: Pre-dose, 2, 3, 4, 10 (pre-evening dose), 12, 13, 14 and 24 hours post-dose up to Day 56
- Cmax 1 and 2: Maximal Peak Concentration (Cmax) for Delamanid Following First and Second Daily DoseTime frame: Pre-dose, 2, 3, 4, 10 (pre-evening dose), 12, 13, 14 and 24 hours post-dose up to Day 56
- Area Under the Plasma Concentration Curve From 0 to 24 Hours (AUC0-24h) for DelamanidTime frame: Pre-dose, 2, 3, 4, 10 (pre-evening dose), 12, 13, 14 and 24 hours post-dose up to Day 56
- Accumulation Ratio for Cmax (Rac[Cmax]) for DelamanidTime frame: Pre-dose, 2, 3, 4, 10 (pre-evening dose), 12, 13, 14 and 24 hours post-dose up to Day 56
- Accumulation Ratio for AUC From Time 0 to 24 Hours (Rac[AUC0-24h]) for DelamanidTime frame: Pre-dose, 2, 3, 4, 10 (pre-evening dose), 12, 13, 14 and 24 hours post-dose up to Day 56
- Time to Maximal Peak Concentration (Tmax) for Delamanid Metabolite (DM)-6704, DM-6705, DM-6706, DM-6717, DM-6718, DM-6720, DM-6721, and DM-6722Time frame: 0 hours (morning pre-dose), 2, 3, 4, 10 (pre-evening dose), 12, 13, 14 and 24 hours post-dose up to Day 56
- Maximal Peak Concentration (Cmax) for DM-6704, DM-6705, DM-6706, DM-6717, DM-6718, DM-6720, DM-6721, and DM-6722Time frame: 0 hours (morning pre-dose), 2, 3, 4, 10 (pre-evening dose), 12, 13, 14 and 24 hours post-dose up to Day 56
- Area Under the Plasma Concentration Curve From 0 to 24 Hours (AUC0-24h) for DM-6704, DM-6705, DM-6706, DM-6717, DM-6718, DM-6720, DM-6721, and DM-6722Time frame: 0 hours (morning pre-dose), 2, 3, 4, 10 (pre-evening dose), 12, 13, 14 and 24 hours post-dose up to Day 56
- Accumulation Ratio for Cmax (Rac[Cmax]) for DM-6704, DM-6705, DM-6706, DM-6717, DM-6718, DM-6720, DM-6721, and DM-6722Time frame: 0 hours (morning pre-dose), 2, 3, 4, 10 (pre-evening dose), 12, 13, 14 and 24 hours post-dose up to Day 56
- Accumulation Ratio for AUC (Rac[AUC]) for DM-6704, DM-6705, DM-6706, DM-6717, DM-6718, DM-6720, DM-6721, and DM-6722Time frame: 0 hours (morning pre-dose), 2, 3, 4, 10 (pre-evening dose), 12, 13, 14 and 24 hours post-dose up to Day 56
- Elimination Half-life (t1/2) for DM-6704, DM-6705, DM-6706, DM-6717, DM-6718, DM-6720, DM-6721, and DM-6722Time frame: 0 hours (morning pre-dose), 2, 3, 4, 10 (pre-evening dose), 12, 13, 14 and 24 hours post-dose on Day 56
Locations
17 sites in 9 countries. Site status is shown where the registry gives one.
University of Texas Health Center at Tyler / Heartland National TB Center / Texas Center for Infectious Disease
San Antonio, Texas
Beijing Chest Hospital
Beijing, China
Shanghai Pulmonary Hospital
Shanghai, China
Abbassia Chest Hospital
Cairo, Egypt
North Estonian Medical Centre Foundation
Tallinn, Estonia
Tartu University Lung Hospital
Tartu, Estonia
Kinki Chuo Chest Hospital
Osaka, Japan
Fukujuji Hospital
Tokyo, Japan
Clinic of Tuberculosis and Lung Diseases
Riga, Latvia
Hospital Nacional Daniel Alcides Carrión
Carrion, Peru
Hospital Nacional Sergio E. Bernales
Lima, Peru
Hospital Nacional Hipolito Unanue
Unánue, Peru
Tropical Disease Foundation
Manila, Philippines
Masan Medical Center
Changwon, South Korea
National Masan Hospital
Masan, South Korea
Younsei University Medical Center (YUMC), Severance Hospital
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.